Synopsis:
Hamps Bio Limited sets September 8, 2025, as the record date for the 1:1 bonus share issue approved at its AGM.
This Penny FMCG Stock, engaged in pharmaceutical formulation marketing and distribution, and manufacturing freeze-dried and frozen food products, hit a 2 percent upper circuit after the board set a record date for a 1:1 bonus issue.
With a market capitalization of Rs. 24.64 crores, the shares of Hamps Bio Limited hit a 2 percent upper circuit of Rs. 56.56 per share on Tuesday, up from its previous closing price of Rs. 55.46 per share.
What is the news?
Hamps Bio Limited’s Board of Directors has fixed Monday, September 08, 2025, as the Record Date for determining the eligibility of shareholders for the allotment of Bonus Equity Shares.
The bonus shares were approved during the 18th Annual General meeting held on Saturday, August 30, 2025. The board has decided to issue bonus shares at a ratio of 1:1, meaning that shareholders will receive one new fully paid-up equity share of Rs. 10 each for every one existing fully paid-up equity share they hold.
Also read: Multibagger Stock Jumps 4% After Receiving International Order from Leading Aircraft OEM
Company Overview
Hamps Bio Limited is an Indian company incorporated in 2007, engaged primarily in pharmaceutical formulation, marketing and distribution as well as manufacturing freeze-dried and frozen products such as fruits, vegetables, herbs, and flowers. The company started as a pharma marketing firm and expanded into FMCG freeze-dried foods in 2017.
The company operates under the brand names “Hamps” for pharma products and “FzyEzy” for its freeze-dried and frozen food division. It sells pharma products mainly in 8 states and union territories and frozen/dried foods in 4 countries and 22 states/UTs.
Its products are sold through a network of over 50 distributors and e-commerce platforms like Amazon and Flipkart. The company has a registered office in Ankleshwar, Gujarat, and has more than 50 employees.
Financial Highlights
Coming into financial highlights, Hamps Bio Limited’s revenue has decreased from Rs. 3.33 crore in H2 FY24 to Rs. 3.13 crore in H2 FY25, which is a drop of 6.01 percent. The net profit has also decreased by 86.96 percent from Rs. 0.23 crore in H2 FY24 to Rs. 0.03 crore in H2 FY25. Hamps Bio Limited’s revenue and net profit have grown at a CAGR of 7.69 percent and 35.72 percent, respectively, over the last three years.
In terms of return ratios, the company’s ROCE and ROE stand at 6.68 percent and 4.94 percent, respectively. Hamps Bio Limited has an earnings per share (EPS) of Rs. 0.69, and its debt-to-equity ratio is 0.34x.
Written By – Nikhil Naik
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
